The Whole Thing consolidates 43 U.S. patent filings across three projects

By AI, Created 5:35 AM UTC, May 25, 2026, /AGP/ – The Whole Thing said it has grouped 43 active U.S. patent filings under one USPTO customer record across three closed-loop projects. The portfolio also cited FDA and ANSI acknowledgments, plus reserved NYSE tickers for two projects, as it builds out climate, medicine and standards research.

Why it matters: - The Whole Thing is trying to turn a broad patent portfolio into a single research architecture spanning climate, medicine and standards work. - The filings could support future commercialization, partnerships or capital raises around three separate projects. - The company also signaled market ambitions by reserving NYSE tickers for two of the projects.

What happened: - The Whole Thing disclosed that 43 active U.S. patent filings have been consolidated under USPTO Customer 226605. - The filings cover three projects tied to a shared closed-loop architecture. - Project Kontrast has reserved the New York Stock Exchange ticker KTRS. - Project Infinity centers on lifecycle medicine research. - Project Institute focuses on international standards research.

The details: - Project Kontrast is described as a closed-loop production architecture intended to source critical minerals and synthetic fuels from atmospheric and oceanic inputs. - Project Infinity includes a Lifecycle hCG Software as a Medical Device research program. - The U.S. Food and Drug Administration acknowledged Q-Submission Q261539 on May 19, 2026, tied to that SaMD research program. - Project Infinity also includes related hardware research filings named KAMNOBA, KMNG, KAMWOMB, KMVPAS, HOH-MAG, KAMBPT, KAMFLOOR and WOMBONES. - Project Institute covers a proposed International Workshop Agreement on Time On Earth as a unit-of-account framework. - The American National Standards Institute acknowledged correspondence related to that proposal. - Project Institute has reserved the NYSE ticker GSCC. - The portfolio is privately held. - The company said strategic partnership and capital-raise inquiries should go to kameron@thewholething.org.

Between the lines: - The structure suggests The Whole Thing is organizing a set of technical efforts into a common platform rather than treating each filing as a standalone project. - FDA and ANSI acknowledgments do not equal product approvals or standards adoption, but they indicate the projects have entered formal review or correspondence channels. - The reserved tickers hint at a public-market narrative even though the portfolio remains private.

What’s next: - The Whole Thing is likely to continue advancing patent prosecution, standards work and regulatory engagement across the three projects. - Partnership and funding discussions could shape how quickly the portfolio moves from filings to deployed programs. - The company points readers to more information and additional background.